Customer Letters

Please note: The following Customer Letters, do not replace the version that you receive from your local Canadian Blood Services site.

* The contents of the customer letters available on this site are current as of their dates of publication. If required, contact your local Hospital Liaison Specialist to determine if the letter is still current.

Displaying 101 - 150 of 394

	Date Sort ascending
CL_2023-18.pdf	2023-07-12	INFORMATION ONLY Revision of Request for RHD Genotyping Form Customer Letter 2023-18 (PDF)
CL_2023-16.pdf	2023-07-10	INFORMATION ONLY New Manual Contingency Process for Release Labelling Customer Letter 2023-16 (PDF)
CL_2023-17.pdf	2023-07-10	ACTION REQUIRED National Deployment of Pathogen-Reduced Platelets: Fifth Update  Customer Letter 2023-17 (PDF)
CL_2023-15.pdf	2023-06-21	INFORMATION ONLY Panzyga, Octagam and Cutaquig Unavailable for Exceptional Access Cases Customer Letter 2023-15 (PDF)
CL_2023-14.pdf	2023-06-16	INFORMATION ONLY Cytogam Shortage – Temporary Supply of US-labelled Cytogam Customer Letter 2023-14 (PDF) \| Important Information on Cytogam Shortage - Temporary Supply of US-labelled Cytogam (PDF)
CL_2023-13.pdf	2023-06-05	ACTION REQUIRED Health Canada Approved - Apheresis Platelets Psoralen-treated and Apheresis Platelets PAS-E Added Customer Letter 2023-13 (PDF)
CL_2023-12.pdf	2023-05-16	ACTION REQUIRED National Deployment of Pathogen-Reduced Platelets: Fourth Update Customer Letter 2023-12 (PDF)
CL_2023-11.pdf	2023-04-27	INFORMATION ONLY FAQ for the Request for Proposals (RFP) for Immunoglobulins and other Plasma Protein and Related Products (PPRP) Customer Letter 2023-11 (PDF) \| 2023 IVIg Transition FAQ (PDF)
CL_2023-10.pdf	2023-04-14	ACTION REQUIRED Shelf Life Extension of Pooled Platelets Psoralen-Treated Components from 5 to 7 Days Customer Letter 2023-10 (PDF)
CL_2023-09.pdf	2023-04-03	ACTION REQUIRED National Deployment of Pathogen-Reduced Platelets: Third Update Customer Letter 2023-09 (PDF)
CL_2023-08.pdf	2023-03-24	INFORMATION ONLY Alprolix and Eloctate Packaging Changes Customer Letter 2023-08 (PDF) \| ALPROLIX Hemophilia B Enrolment Form (PDF) \| ELOCTATE Hemophilia A Enrolment Form (PDF) \| ALPROLIX - ELOCTATE Notification Letter (PDF)
CL_2023-07.pdf	2023-03-23	INFORMATION ONLY NAC Recommendations for the Use of Solvent-Detergent Plasma in Canada; Important Changes to Post Thaw Storage of Octaplasma Customer Letter 2023-07 (PDF) \| Octaplasma^®Advisory Letter (PDF)
CL_2023-06.pdf	2023-03-20	INFORMATION ONLY Vonvendi^® - Interim Plasma Protein and Related Products Review Decision Customer Letter 2023-06 (PDF)
CL_2023-05.pdf	2023-03-13	ACTION REQUIRED Information on Immunoglobulin Inventory Following Results of the Request for Proposals (RFP) for Plasma-Derived Plasma Protein and Related Products (PPRP) Customer Letter 2023-05 (PDF)
CL_2023-04.pdf	2023-02-07	INFORMATION ONLY Further Information on Expanded Use of Solvent Detergent Plasma: Education Materials and Ordering Information Customer Letter 2023-04 (PDF) \| Octaplasma^®Customer Letter (PDF) \| Octaplasma^® - Q&A for Transfusion Medicine Laboratory (PDF)
CL_2023-03.pdf	2023-02-06	ACTION REQUIRED National Deployment of Pathogen-Reduced Platelets: Second Update Customer Letter 2023-03 (PDF)
CL_2023-02.pdf	2023-01-27	INFORMATION ONLY Update to Label Changes for Rare International Red Blood Cells Customer Letter 2023-02 (PDF) \| Attachment 1 (PDF)
CL_2023-01.pdf	2023-01-10	INFORMATION ONLY Further Information on Expanded Use of Solvent Detergent Plasma: Updated Post Thaw Expiration, Sample Labels and Implementation Checklist Customer Letter 2023-01 (PDF) \| Recommended Solvent Detergent Plasma Hospital Implementation Checklist (PDF) \| Octaplasma: Blood Bank Communication (PDF) \| Octaplasma B Label Mockup (PDF) \| Octaplasma A Label Mockup (PDF) \| Octaplasma AB Label Mockup (PDF) \| Octaplasma O Label Mockup (PDF)
CL_2022-37.pdf	2022-12-22	INFORMATION ONLY 2022 Holiday Message and Inventory Update Customer Letter 2022-37 (PDF)
CL_2022-36.pdf	2022-12-20	INFORMATION ONLY Factor XI Packaging Change Customer Letter 2022-36 (PDF) \| Factor XI Packaging Change (PDF)
CL_2022-35.pdf	2022-12-09	INFORMATION ONLY Eloctate 2000IU Supply Update Customer Letter 2022-35 (PDF)
CL_2022-34.pdf	2022-12-01	ACTION REQUIRED Introducing Apheresis Platelets in PAS, Pathogen-reduced and Untreated, with New ISBT Component Codes Customer Letter 2022-34 (PDF)
CL_2022-33.pdf	2022-11-24	INFORMATION ONLY Correction - Expanded Use of Solvent Detergent Plasma Customer Letter 2022-33 (PDF)
CL_2022-32.pdf	2022-11-21	INFORMATION ONLY Immunoglobulin Inventory Depletion Following Results of the Request for Proposals (RFP) for Plasma-Derived Plasma Protein and Related Products (PPRP) Customer Letter 2022-32 (PDF)
CL_2022-31.pdf	2022-11-18	ACTION REQUIRED Business Continuity and Product Order Forms Customer Letter 2022-31 (PDF)
CL_2022-30.pdf	2022-11-14	ACTION REQUIRED National Deployment of Pathogen-Reduced Platelets: First Update Customer Letter 2022-30 (PDF)
CL_2022-29.pdf	2022-11-14	INFORMATION ONLY Minor visual changes to storage containers for Apheresis Platelet and Apheresis Frozen Plasma (ACD-A) Customer Letter 2022-29 (PDF) \| Terumo notification letter (PDF)
CL_2022-28.pdf	2022-11-10	INFORMATION ONLY Expanded Use of Solvent Detergent Plasma Customer Letter 2022-28 (PDF) \| Octaplasma Blood Bank Communication (PDF)
CL_2022-27.pdf	2022-11-07	INFORMATION ONLY Implementation of Leukoreduced Whole Blood in Canadian Forces Health Services
CL_2022-26.pdf	2022-10-31	INFORMATION ONLY Update Donor High Titre Isohemagglutinin (Anti-A / Anti-B) Testing Customer Letter 2022-26 (PDF)
CL_2022-25.pdf	2022-10-19	INFORMATION ONLY Revised Date for the Implementation of Label and Product Code Changes for Rare International Red Blood Cells Customer Letter 2022-25 (PDF)
CL_2022-24.pdf	2022-10-11	INFORMATION ONLY Temporary Changes to the Packaging Components for WinRho^® SDF 300mcg Customer Letter 2022-24 (PDF) \| Kamada Hospital Letter (PDF)
CL_2022-23.pdf	2022-10-03	INFORMATION ONLY Updated Product Monograph for Esperoct^® Customer Letter 2022-23 (PDF) \| Product Monograph Including Patient Medication Information (PDF) \| Patient Medication Information Leaflet (PDF)
CL_2022-22.pdf	2022-09-20	INFORMATION ONLY Results of RFP for Plasma Derived PPRP Customer Letter 2022-22 (PDF)
CL_2022-21.pdf	2022-09-09	ACTION REQUIRED Introducing New Formats of HyperHep B^® Customer Letter 2022-21 (PDF) \| HyperHEP B^® - Product Update (PDF)
CL_2022-20.pdf	2022-08-05	INFORMATION ONLY Kamada acquiring Hyperimmune Products from Saol Customer Letter 2022-20 (PDF) \| Kamada Customer Letter (PDF)
CL_2022-19.pdf	2022-07-29	INFORMATION ONLY Ink Issues on Fresh Blood Component Labels Customer Letter 2022-19 (PDF)
CL_2022-18.pdf	2022-07-22	ACTION REQUIRED Plans for National Deployment of Pathogen Reduced Platelets and Plasma Customer Letter 2022-18 (PDF)
CL_2022-17.pdf	2022-07-13	INFORMATION ONLY Eloctate 2000IU Supply Update Customer Letter 2022-17 (PDF)
CL_2022-16.pdf	2022-07-12	ACTION REQUIRED Label and Product Code Changes for Rare International Red Blood Cells Customer Letter 2022-16 (PDF)
CL_2022-15.pdf	2022-07-05	INFORMATION ONLY New Administrator for ProCare Patient Support Program Customer Letter 2022-15 (PDF) \| Procare Patient Advisory Letter (PDF) \| Procare HCP Advisory Letter (PDF)
CL_2022-14.pdf	2022-06-15	INFORMATION ONLY Donor High Titre Isohemagglutinin (Anti-A /Anti-B) Testing Customer Letter 2022-14 (PDF)
CL_2022-13.pdf	2022-06-09	INFORMATION ONLY Partnering to Improve Red Blood Cell Utilization Customer Letter 2022-13 (PDF)
CL_2022-12.pdf	2022-04-11	INFORMATION ONLY Adynovate^® Ancillary Item Changes Customer Letter 2022-12 (PDF) \| ADYNOVATE^® changes and timelines(PDF)
CL_2022-11.pdf	2022-04-08	ACTION REQUIRED Changes to the Hospital Customer Feedback Process Customer Letter 2022-11 (PDF)
CL_2022-10.pdf	2022-03-21	INFORMATION ONLY 2021 Recombinant Request for Proposals - Zonovate® and Esperoct® Availability & Updates to the Request for Patient Designated Plasma Protein & Related Products Form Customer Letter 2022-10 (PDF) \| Esperoct Welcome Letter (PDF) \| Zonovate Welcome Letter (PDF) \| Zonovate Product Profile (PDF) \| Esperoct Product Profile (PDF) \| F801219 Sample (PDF)
CL_2022-09.pdf	2022-03-18	INFORMATION ONLY Discontinuation of Apheresis Fresh Frozen Plasma 500mL Customer Letter 2022-09 (PDF)
CL_2022-08.pdf	2022-03-14	INFORMATION ONLY J82 Biodegradable Insulator Switchover Customer Letter 2022-08 (PDF)
CL_2022-07.pdf	2022-02-10	INFORMATION ONLY Recommendations for Recipient Notification for Blood Component Recalls Related to COVID-19 Customer Letter 2022-07 (PDF) \| National Recipient Advisory Committee Recommendation (PDF)
CL_2022-06.pdf	2022-02-09	INFORMATION ONLY FAQ for the Request for Proposals (RFP) for Recombinant Plasma Protein and Related Products (PPRP) Customer Letter 2022-06 (PDF) \| 2021 Recombinant RFP FAQ: Process, Results, and Product Availability (PDF)